secwatch.observer — SEC 8-K summary
======================================

Issuer:     Elicio Therapeutics, Inc. (ELTX)
CIK:        0001601485
Form:       8-K
Filed at:   2023-06-02T23:59:59+00:00
Accession:  0001140361-23-028077
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.90
Item codes: 2.01, 3.03, 4.01, 5.01, 5.02, 5.03, 5.07, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Angion completes merger with Elicio, becomes Elicio Therapeutics; ticker changes to ELTX
--------------------------------------------------------------------------------

- Merger completed June 1, 2023; Elicio stockholders received 0.0181 Angion shares per Elicio share, issuing ~5.38M shares.
- Prior Elicio equity holders own ~65.2% of combined company; prior Angion holders own ~34.8% on fully diluted basis.
- Company renamed Elicio Therapeutics, Inc.; ticker changes from ANGN to ELTX effective June 2; reverse stock split 10:1.
- Board reconstituted to 9 directors (6 Elicio designees); Robert Connelly (former Elicio CEO) becomes CEO; new CFO Brian Piekos.
- Independent auditor changed: Moss Adams dismissed, Baker Tilly engaged (was Elicio's auditor).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1601485/000114036123028077/0001140361-23-028077-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1601485/000114036123028077/brhc20053890_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-028077

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer